National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Inotersen (TegsediĀ®) is indicated for the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin (TTR) amyloidosis (hATTR).


NCPE Assessment Process Ongoing
Rapid review commissioned 26/08/2019
Rapid review completed 07/10/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of inotersen compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.